Treatment-free remission after two-year consolidation therapy with nilotinib in patients with chronic myeloid leukemia: STAT2 trial in Japan

The purpose of this trial was to evaluate the efficacy of 2-year consolidation therapy with nilotinib, at a dose of 300 mg twice daily, for achieving treatment-free remission in chronic myeloid leukemia patients with a deep molecular response (BCR-ABL1(IS) ≤0.0032%). Successful treatment-free remiss...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Haematologica
Hlavní autoři: Takahashi, Naoto, Nishiwaki, Kaichi, Nakaseko, Chiaki, Aotsuka, Nobuyuki, Sano, Koji, Ohwada, Chikako, Kuroki, Jun, Kimura, Hideo, Tokuhira, Michihide, Mitani, Kinuko, Fujikawa, Kazuhisa, Iwase, Osamu, Ohishi, Kohshi, Kimura, Fumihiko, Fukuda, Tetsuya, Tanosaki, Sakae, Takahashi, Saori, Kameoka, Yoshihiro, Nishikawa, Hiroyoshi, Wakita, Hisashi
Médium: Artigo
Jazyk:Inglês
Vydáno: Ferrata Storti Foundation 2018
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6278957/
https://ncbi.nlm.nih.gov/pubmed/29976734
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2018.194894
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky